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Abstract
Introduction: Emerging evidence suggests that long-term 
pulmonary symptoms and functional impairment occurs in 
a proportion of individuals following SARS-CoV-2 infection. 
Although the proportion of affected patients remains to be 
determined, physicians are increasingly being confronted 
with patients reporting respiratory symptoms and impair-
ment beyond the acute phase of COVID-19. In face of limited 
evidence, the Swiss Society for Pulmonology established a 
working group to address this area of unmet need and for-
mulated diagnostic and treatment recommendations for the 
care of patients with pulmonary long COVID (LC). Method: 
The Swiss COVID Lung Study group and Swiss Society for 
Pulmonology (SSP) formulated 13 questions addressing the 
diagnosis and treatment of pulmonary LC. A survey within 
the SSP special interest groups involved in care of LC pa-
tients was conducted in Switzerland. A CORE process/Del-
phi-like process was used to formulate recommendations. 
Forty experienced pulmonologists replied to the first survey 
and 22 completed the second follow-up survey. Agreement 
of ≥70% consensus led to formulation of a recommendation. 
Results: The participants in the survey reached consensus 
and formulated a strong recommendation for regarding the 
following points. Patients hospitalized for COVID-19 should 
have a pulmonary assessment including pulmonary func-
tion tests. Symptomatic subjects affected by COVID-19, in-
cluding those with mild disease, should benefit from a pul-
monary follow-up. Persistent respiratory symptoms after 
COVID-19 should be investigated by a pulmonary follow-up 
including plethysmography, diffusion capacity measure-
ment, and blood gases analysis. Individuals having suffered 
from COVID-19 and who present with persistent respiratory 
symptoms should be offered a rehabilitation. Additional 
questions were given moderate or weak recommendations 
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for. The panel did not reach sufficient consensus for pharma-
cological therapy (e.g., therapy specifically targeting lung fi-
brosis) to formulate recommendations for LC drug treat-
ment. Conclusion: The formulated recommendations should 
serve as an interim guidance to facilitate diagnosis and treat-
ment of patients with pulmonary LC. As new evidence 
emerges, these recommendations may need to be adapted.
© 2021 The Author(s)
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Summary of Recommendations
Question 1: Should All Patients Hospitalized for COVID-19 
Have a Pulmonary Follow-Up?
• All patients hospitalized for COVID-19 should have a pulmo-
nary follow-up. (strong recommendation for, consensus 
reached)
• The suggested time frame is within 3 months after infection. 
(suggestion, no consensus)
Question 2: Should All COVID-19 Affected Patients Including 
Those with Mild Disease Have a Pulmonary Follow-Up, if 
Symptomatic?
• All COVID-19 affected patients, including those with mild dis-
ease, should have a pulmonary follow-up, if symptomatic. 
(strong recommendation for, consensus reached)
• The suggested time frame is within 3 months after infection. 
(suggestion, no consensus)
Question 3: Should All Patients with Persistent Respiratory 
Symptoms after COVID-19 Have a Pulmonary Follow-Up 
Including Plethysmography, Diffusion Capacity Measurement, 
and Blood Gases Analysis?
• All patients with persistent respiratory symptoms after CO-
VID-19 should have a pulmonary follow-up including plethys-
mography, diffusion capacity measurement, and blood gases 
analysis. (strong recommendation for, consensus reached)
Question 4: Should All Patients with Severe COVID-19 
(WHO Definition) Have a Pulmonary Follow-Up Including 
Plethysmography and Diffusion Capacity, Blood Gases 
Analysis Independent of Symptom Persistence?
• For patients with severe COVID-19 (WHO definition), a pul-
monary follow-up is recommended including plethysmogra-
phy and diffusion capacity, blood gases analysis independently 
of symptom persistence. (moderate recommendation for, con-
sensus reached when strong and weak recommendations are 
merged)
• Remark: Consensus was reached when strong and weak recom-
mendations are merged, 64% gave a strong recommendation 
for and 36% a weak recommendation for.
Question 5: Should Exercise Testing (e.g., 6MWD or 
Equivalent) be Routinely Performed after COVID-19?
• Exercise testing (e.g., 6MWD or equivalent) is recommended 
after COVID-19. (weak recommendation for, consensus 
reached)
Question 6: Should Chest CT Scan Be Routinely Performed 
in Patients with Persisting Respiratory Symptoms after 
COVID-19?
• Chest CT scan is recommended to be routinely performed in 
patients with persisting respiratory symptoms after CO- 
VID-19. (moderate recommendation for, consensus reached 
when strong and weak recommendations are merged)
• Remark: Consensus was reached when strong and weak recom-
mendations are merged, 68% gave a strong recommendation 
for and 32% a weak recommendation for.
Question 7: Should Cardio-Pulmonary Exercise Test Be 
Routinely Performed after COVID-19 with Persistent 
Symptoms?
• Cardio-pulmonary exercise test (CPET) is recommended to be 
routinely performed after COVID-19 with persistent symp-
toms. (moderate recommendation for, consensus reached 
when strong and weak recommendations are merged)
• Remark: Consensus was reached when strong and weak recom-
mendations are merged, 14% gave a strong recommendation 
for and 68% a weak recommendation for.
Question 8: Should Patients with Persistent Symptoms after 
COVID-19 Have Access to Specialized Multidisciplinary Post-
COVID-19 Clinics or Networks?
• Patients with persistent symptoms after COVID-19 are recom-
mended to have access to specialized multidisciplinary Post-
COVID-19 clinics or networks. (moderate recommendation 
for, consensus reached when strong and weak recommenda-
tions are merged)
• Remark: Consensus was reached when strong and weak recom-
mendations are merged, 55% gave a strong recommendation 
for and 41% a weak recommendation for.
Question 9: Should Patients after COVID-19 Who Present 
with New Onset Obstructive Lung Disease Have Empiric Topic 
Inhaled or Systemic Steroid Treatment?
• Patients after COVID-19 who present with new obstructive 
lung disease are recommended to be offered empiric topic in-
haled or systemic steroid treatment. (moderate recommenda-
tion for, consensus reached when strong and weak recommen-
dations are merged)
• Remark: Consensus was reached when strong and weak recom-
mendations are merged, 36% gave a strong recommendation 
for and 36% a weak recommendation for.
Question 10: Should Patients after COVID-19 Who Present 
with Persistent Cough Have Empiric Inhaled Topic Steroids?
• Patients after COVID-19 who present with persistent cough 
are recommended to have empiric inhaled topic steroids. 
(moderate recommendation for, consensus reached when 
strong and weak recommendations are merged)
• Remark: Consensus was reached when strong and weak recom-
mendations are merged, 32% gave a strong recommendation 
for and 45% a weak recommendation for.




Question 11: Should Patients after COVID-19 Who Present 
with Interstitial Abnormalities after Exclusion of an Active 
Infection Receive an Empiric Systemic Steroid Trial?
• Patients after COVID-19 who present with interstitial abnor-
malities after exclusion of an active infection are recommended 
to be evaluated to receive an empiric systemic steroid trial. 
(moderate recommendation for, consensus reached when 
strong and weak recommendations are merged)
• Remark: Consensus was reached when strong and weak recom-
mendations are merged, 14% gave a strong recommendation 
for and 59% a weak recommendation for.
Question 12: Should Patients after COVID-19 Who Present 
with Signs of Pulmonary Fibrosis Receive Specific Antifibrotic 
Drugs?
• It is unclear whether patients after COVID-19 who present 
with signs of pulmonary fibrosis should receive specific antifi-
brotic drugs. (suggestion for no recommendation, no consen-
sus)
Question 13: Should Patients after COVID-19 Who 
Present with Persistent Respiratory Symptoms Undergo a 
Rehabilitation Program?
• Patients after COVID-19 who present with persistent respira-
tory symptoms are recommended to undergo a rehabilitation 
program. (strong recommendation for, consensus reached)
Introduction
Previous Coronavirus infections, including Severe Acute 
Respiratory Syndrome (SARS) [1] and Middle East respira-
tory syndrome (MERS), [2] were associated with a high 
mortality, pulmonary complications including acute respi-
ratory distress syndrome (ARDS), and long-term sequelae 
in survivors [3, 4]. COVID-19 caused by SARS-CoV2, has 
a similar initial clinical presentation as SARS and MERS. 
Initial symptoms include fever, cough and dyspnea, and bi-
lateral opacities may be observed radiologically. ARDS is 
also a major respiratory complication in COVID-19, par-
ticularly in elderly patients [5, 6]. ARDS itself can result in 
pulmonary sequelae and long-term impairment [7]. 
Whether pulmonary sequelae after coronavirus infections 
are linked to ARDS [7] or are related to virus-specific mech-
anisms of disease remains to be clarified [8, 9].
Cumulative literature addresses persisting pulmonary 
and extrapulmonary symptoms after acute COVID-19 
infection [10, 11]. These symptoms and associated organ 
manifestations are increasingly referred to as long CO-
VID (LC) syndrome, although a universal definition is 
still missing. The post-acute COVID-19 period is consid-
ered in the presence of symptoms up to 3 weeks after in-
fection, while LC persists beyond 12 weeks after infection 
[12, 13].
The characteristics and time-points of LC manifesta-
tions vary between 3 and 12 weeks after acute infection 
[12, 13]. Persistence of symptoms that last more than 2 or 
3 months beyond the COVID-19 infection without alter-
native diagnosis have been described [14, 15]. A modified 
proposal for a definition according to these recent publi-
cations is shown in Table 1. The causes for symptom per-
sistence and organ impairment are unknown, but hy-
potheses range from immunological phenomena, persis-
tent subclinical virus infection, post-ICU syndrome to 
diffuse thrombotic damage due to endotheliitis [13, 16].
Long COVID-19 treatment programs and multidisci-
plinary/interdisciplinary LC consultations are increasingly 
being set up [17]. Although calls are made and efforts initi-
ated to formulate guidance for physicians for treating pa-
tients with persistent symptoms or LC [18, 19], scientific 
evidence to support clinically meaningful guidelines is 
sparse. Switzerland has been one of the first European coun-
tries affected by the ongoing pandemic of COVID-19 in 
spring 2020. Persistence of respiratory symptoms 4 months 
after the infection has been investigated within a Swiss wide 
national observational study for lung sequelae (Swiss CO-
VID Lung Study: NCT04581135), showing that respiratory 
impairment is most pronounced in patients following se-
vere disease [20]. Diagnostic and treatment approaches of 
patients after COVID-19 have not been defined yet.
Table 1. Modified proposal for the definition of acute and long COVID [15]
Acute COVID-19 Signs and symptoms of COVID-19 for up to 4 weeks
Ongoing symptomatic COVID-19 Signs and symptoms of COVID-19 from 4 weeks up to 12 weeks
Post-COVID-19 syndrome Signs and symptoms that develop during or after an infection consistent with COVID-19, 
continue for more than 12 weeks and are not explained by an alternative diagnosis
Long COVID Long COVID describes signs and symptoms that continue or develop after acute COVID-19; 
it includes both ongoing symptomatic COVID-19 (from 4 to 12 weeks) and post-COVID-19 




The Swiss COVID Lung Study group and SSP have 
conducted a survey within its special interest group (SIG) 
involved in care of COVID-19 patients to evaluate inter-
im recommendations by its members for treatment of in-
dividuals with LC. Members of the SSP SIG Sleep Breath-
ing Disorders, Prevention (tobacco/environment), Pul-
monary Vascular Disease, Obstructive Lung Diseases & 
Allergy, Thoracic Interventions & Oncology, Infections, 
Tuberculosis, CF/non-CF Bronchiectasis, Functional Di-
agnostics and Sports Pulmonology, Interstitial and Rare 
Lung Diseases and Ventilation and O2 participated in the 
survey, and names of participants are listed in the Ac-
knowledgements.
In absence of clinical evidence, the Convergence of 
Opinion on Recommendations and Evidence (CORE) 
process/Delphi-like process is an adequate tool to formu-
late recommendations for physicians that need to be 
adapted before evidence accumulates and international 
consensus becomes available [21]. Questions were for-
mulated with PICO (Population, Intervention, Compari-
son, and Outcome) format by an expert core committee 
listed as authors. The questions were discussed in a video 
conference on January 25th, 2021 by the participants to 
ensure that they accurately conveyed their intent, were 
clearly written, and all terms have been defined. Due to 
the current pandemic with restricted possibilities for 
face-to-face exchange, subsequent discussions were con-
ducted virtually or by email exchange.
The electronic survey was conducted by LamaPoll® 
sent to all members of the SSP SIGs listed above. For each 
question, the respondent had to choose among a strong 
or weak recommendation for or against the course of ac-
tion or no recommendation; participants also had the op-
portunity to provide written comments.
A second survey was subsequently issued that was 
identical to the first, with the exception that numerical 
responses and comments from the first survey were pro-
vided.
Agreement of ≥70% consensus led to formulation of a 
recommendation. If consensus could not be reached, no 
recommendation was provided, but a suggestion was for-
mulated, if possible. If a majority of the survey partici-
pants decided for a strong or weak recommendation 
(≥70% if combined), consensus for a recommendation 
for was assumed and a moderate recommendation was 
provided.
The committee held another videoconference to dis-
cuss the survey results on March 31st, 2021. The sum-
mary and conclusions of this discussion were integrated 
into the manuscript.
A total of 40 pulmonologists from all parts of Switzer-
land responded to the first and 22 participated in the sec-
ond survey. Most pulmonologist had extensive experience 
with acute COVID-19 patients (42% in the first and 55% 
in the second survey with >50 acute COVID-19 patients). 
More than 56% (68% in the second survey) treated up to 
50 LC patients at the time of the survey, while only 14% 
were in charge of more than 50 LC patients in both sur-
veys. This discrepancy between acute and LC care may be 
related to the time point of the survey before the end of the 
second wave in February 2021. As experience with LC was 
more extensive in the second survey and probably physi-
cians with specific interest in pulmonary LC replied the 
second round, the results of the second survey were used 
to define consensus for recommendations.
Results of the Swiss National Survey among 
Pulmonologists
An overview of the recommendations and suggestions 
is provided in a summarized form including individual 
survey results in Table 2.
Question 1: Should All Patients Hospitalized for 
COVID-19 Have a Pulmonary Follow-Up?
Literature Review
Most patients hospitalized for COVID-19 pneumonia 
have persistent symptoms after 3–4 months [22]. Forty-
two percent of these patients report dyspnea, indicating 
persistent pulmonary impairment after acute infection 
[22]. In a Norwegian study 3 months after COVID-19, 
symptoms persisted in half of the patients with one-quar-
ter having reduced diffusion capacity [23]. These findings 
were also confirmed by an Austrian study group [24]. In 
a Swiss study, specifically those with ARDS showed lung 
functional impairment with mainly reduced diffusion ca-
pacity 4 months after acute infection [20]. After severe 
COVID-19, lung functional abnormalities with impaired 
diffusion capacity persisted until 6 months in a recent 
publication [25]. Pulmonary follow-up was already sug-
gested early in the pandemic before evidence for pulmo-
nary sequelae emerged [26]. National German S3 Recom-
mendations for treatment of hospitalized COVID pa-
tients suggest a clinical follow-up after 8–12 weeks to 
detect long-term sequelae, if possible within a study or 
registry [27].




Table 2. Overview of the voting results for each question from both surveys
Question Survey results 1 Survey results 2
1. Should all patients hospitalized for COVID-19 have a 
pulmonary follow-up?









2. Should all COVID-19 affected patients including those with 
mild disease have a pulmonary follow-up, if symptomatic?









3. Should all patients with persistent respiratory symptoms after 
COVID-19 have a pulmonary follow-up including 






4. Should all patients with severe COVID-19 (WHO definition) 
have a pulmonary follow-up including plethysmography and 
diffusion capacity, blood gases analysis independently of 
symptom persistence?
Moderate recommendation for
consensus reached when merged
(49% strong recommendation for 44% weak 
recommendation for)
Moderate recommendation for
consensus reached when merged (64% 
strong recommendation for 36% weak 
recommendation for)
5. Should exercise testing (e.g., 6MWD or equivalent) be 
routinely performed after COVID-19?
Moderate recommendation for
consensus reached when merged




(0% strong recommendation for 77% 
weak recommendation for)
6. Should chest CT scan be routinely performed in patients with 
persisting respiratory symptoms after COVID-19?
Moderate recommendation for
consensus reached when merged
(40% strong recommendation for 42% weak 
recommendation for)
Moderate recommendation for
consensus reached when merged
(68% strong recommendation for 32% 
weak recommendation for)
7. Should cardio-pulmonary exercise test (CPET) be routinely 
performed after COVID-19 with persistent symptoms?
Weak suggestion for
no consensus
(23% strong recommendation for 42% weak 
recommendation for)
Moderate recommendation for
consensus reached when merged
(14% strong recommendation for 68% 
weak recommendation for)
8. Should patients with persistent symptoms after COVID have 
access to specialized multidisciplinary Post COVID-19 clinics or 
networks?
Moderate recommendation for
consensus reached when merged
(65% strong recommendation for 8% weak 
recommendation for)
Moderate recommendation for
consensus reached when merged
(55% strong recommendation for 41% 
weak recommendation for)
9. Should patients after COVID-19 who present with new 
obstructive lung disease have empiric topic inhaled or systemic 
steroid treatment?
Moderate recommendation for
consensus reached when merged
(33% strong recommendation for 37% weak 
recommendation for)
Moderate recommendation for
consensus reached when merged
(36% strong recommendation for 36% 
weak recommendation for)
10. Should patients after COVID-19 who present with persistent 
cough have empiric inhaled topic steroids?
Weak suggestion for
no consensus
(12% strong recommendation for 49% weak 
recommendation for)
Moderate recommendation for
consensus reached when merged
(32% strong recommendation for 45% 
weak recommendation for)
11. Should patients after COVID-19 who present with 
interstitial abnormalities after exclusion of an active infection 
receive an empiric systemic steroid trial?
Weak suggestion for
no consensus
(16% strong recommendation for 40% weak 
recommendation for)
Moderate recommendation for
consensus reached when merged
(14% strong recommendation for 59% 
weak recommendation for)
12. Should patients after COVID-19 who present with signs of 
pulmonary fibrosis receive specific antifibrotic drugs?
Suggestion for no recommendation
no consensus
(40% no recommendation)
Suggestion for no recommendation
no consensus
(55% no recommendation)
13. Should patients after COVID-19 who present with persistent 








The committee discussed the need for a pulmonary 
follow-up in patients after hospitalization. There was 
agreement within the committee that a pulmonary fol-
low-up in patients after hospitalization with COVID-19 
is useful and should be performed within 3 months after 
initial symptoms.
A post-COVID-19 pulmonary follow-up includes, but 
is not limited to, specific assessment of respiratory com-
plaints and history of COVID-19, physical examination 
and appropriate lung function exploration. The pulmo-
nary follow-up can be backed by specific and generic 
quality of life questionnaires, specific laboratory investi-
gations (e.g., SARS-CoV2 antibody confirmation), and 
imaging studies.
SGP/SSP Recommendation
• All patients hospitalized for COVID-19 should have a 
pulmonary follow-up. (strong recommendation for, 
consensus reached)
• The suggested time frame is within 3 months after in-
fection. (suggestion, no consensus)
Remarks for Question 1: Should all patients hospital-
ized for COVID-19 have a pulmonary follow-up? 70% 
(second survey: 77%) strong recommendation for, 26% 
(second survey: 18%) weak recommendation for, 0% 
(second survey: 0%) strong recommendation against, 5% 
(second survey: 5%) weak recommendation against, 0% 
(second survey: 0%) no recommendation.
Remarks for additional question: At what time point 
should respiratory tests be performed? 20% (second sur-
vey: 10%) after 1 month, 17% (second survey: 14%) after 
2 months, 49% (second survey: 62%) after 3 months, 2% 
(second survey: 0%) after 4 months, 12% (second survey: 
14%) gave no recommendation.
Question 2: Should All COVID-19 Affected Patients 
Including Those with Mild Disease Have a Pulmonary 
Follow-Up if Symptomatic?
Literature Review
A recent study showed that in patients who did not 
require hospitalization for COVID-19 pneumonia, about 
half remained symptomatic after 2 months and had lung 
functional abnormalities [28]. As most other studies and 
current data focus on hospitalized patients, it is difficult 
to evaluate lung functional impairment in patients with 
mild disease courses. Nevertheless, symptomatic patients 
might benefit from exclusion of treatable causes of dys-
pnea.
Committee Discussion
The committee discussed the necessity to further in-
vestigate patients with persisting respiratory symptoms. 
These investigations should take place within 3 months 
after symptoms of acute COVID-19.
SGP/SSP Recommendation
• All COVID-19 affected patients, including those with 
mild disease, should have a pulmonary follow-up if 
symptomatic. (strong recommendation for, consensus 
reached)
• The suggested time frame is within 3 months after in-
fection. (suggestion, no consensus)
Remarks for Question 2: Should all COVID-19 affected 
patients including those with mild disease have a pulmo-
nary follow-up if symptomatic? 74% (second survey: 
82%) strong recommendation for, 23% (second survey: 
14%) weak recommendation for, 2% (second survey: 0%) 
strong recommendation against, 0% (second survey: 0%) 
weak recommendation against, 0% (second survey: 5%) 
no recommendation.
Remarks for additional question: At what time point 
should respiratory tests be performed? 24% (second sur-
vey: 5%) after 1 month, 12% (second survey: 10%) after 2 
months, 48% (second survey: 62%) after 3 months, 5% 
(second survey: 0%) after 4 months, 12% (second survey: 
24%) gave no recommendation.
Question 3: Should All Patients with Persistent 
Respiratory Symptoms after COVID-19 Have a 
Pulmonary Follow-Up Including Plethysmography, 
Diffusion Capacity Measurement, and Blood Gases 
Analysis? 
Literature Review
Since the beginning of the SARS-CoV2 pandemic, sev-
eral cohort studies examining pulmonary function tests 
(PFTs) at various time points have been conducted. In-
cluded patients were mostly admitted with severe or 
moderate disease. The vast majority was on oxygen ther-
apy, noninvasive ventilation, high flow nasal cannula or 
mechanical ventilation during the acute phase of the CO-
VID-19. PFTs were assessed at discharge, 30 days, 4 
months [29], and up to 6 months [25]. Overall, the carbon 
monoxide transfer capacity (TLCO) was uniformly re-
duced while forced vital capacity (FVC) and forced expi-
ratory volume in 1 s (FEV1) were within normal range in 
most cases. Patients with more severe acute infection had 
lower TLCO value. FVC and total lung capacity (TLC) 
were reduced only in the patients with the most severe 
acute infection. Huang et al. [25] observed that 56% of the 




patients treated with mechanical ventilation had TLCO 
below 80% predicted after 6 months. Among those who 
received oxygen therapy or no oxygen, reduced TLCO 
was measured in 29 and 22%, respectively [25]. Obstruc-
tive patterns on spirometry were not observed in these 
studies.
What lessons can be learned from previous coronavi-
rus epidemics? SARS-CoV-1 and Middle East respiratory 
syndrome (MERS) caused a long-term decline in lung 
function. Between 6 months and 2 years after infection 
with SARS-CoV-1, there was a decrease in TLCO and 
TLC (restrictive syndrome) in 15.5–43.6% and 5.2–10.9% 
of cases, respectively [3, 4]. In survivors of MERS, TLCO 
was still reduced in 37% 12 months after acute infection 
[30].
Low TLCO in patients with LC is associated with in-
terstitial infiltrates on chest CT scan. The available studies 
do not detail arterial blood gas analysis after acute CO-
VID-19.
Committee Discussion
Evaluation of persistent respiratory symptoms is an 
indication to perform PFTs [31]. The panel specified that 
plethysmography should be performed on top of spirom-
etry and diffusion capacity measurements if these are ab-
normal, to provide assessment of a possible restrictive 
ventilatory defect. The panel suggests performing arterial 
blood gas measurements in patients with low transcuta-
neous oxygen saturation at rest (SpO2 <92%), desatura-
tion on exercise (SpO2 <90%), or receiving supplemental 
domiciliary oxygen therapy.
SGP/SSP Recommendation
• All patients with persistent respiratory symptoms after 
COVID-19 should have a pulmonary follow-up in-
cluding plethysmography, diffusion capacity mea-
surement and blood gases analysis. (strong recom-
mendation for, consensus reached)
Remarks for Question 3: Should all patients with per-
sistent respiratory symptoms after COVID-19 have a pul-
monary follow-up including plethysmography, diffusion 
capacity measurement and blood gases analysis? 91% 
(second survey: 100%) strong recommendation for, 5% 
(second survey: 0%) weak recommendation for, 0% (sec-
ond survey: 0%) strong recommendation against, 2% 
(second survey: 0%) weak recommendation against, 2% 
(second survey: 0%) no recommendation.
Question 4: Should All Patients with Severe 
COVID-19 (WHO Definition) Have a Pulmonary 
Follow-Up Including Plethysmography and Diffusion 
Capacity, Blood Gases Analysis Independently of 
Symptom Persistence?
Literature Review
Early observations found impaired diffusion capacity 
in patients after COVID-19 hospital discharge [29], and 
half of patients had impaired lung function after 30 days 
[32]. Our recent study showed impaired oxygen uptake 
up to 4 months after severe or critical COVID-19 [20]. An 
overview about current studies with lung functional mea-
surements after severe disease is provided in online sup-
plementary Table 1 (for all online suppl. material, see 
www.karger.com/doi/10.1159/000517255). Whether the 
reduced diffusion capacity is due to alveolar surface loss, 
interstitial fibrosis, or vascular impairment cannot be 
judged from this value alone [33–35]. Plethysmography 
is helpful to detect a restrictive ventilator defect, as ob-
served in pulmonary fibrosis and described after CO-
VID-19 [36]. Arterial blood gas analysis facilitates diag-
nosis of hypoxemia, which may be associated with im-
paired diffusion capacity.
Most data on lung functional impairment emerge 
from prospective research cohort COVID-19 follow-up 
studies. Recent publications indicate that pulmonary im-
pairment is more prevalent after severe disease [20, 25].
Committee Discussion
Assessment of disease impact is an additional indica-
tion to perform PFTs [31]. The committee agreed that a 
routine pulmonary follow-up is justified in those patients 
in which severe pulmonary sequelae are expected and 
that require evaluation for treatment.
SGP/SSP Recommendation
• For patients with severe COVID-19 (WHO defini-
tion), a pulmonary follow-up is recommended, in-
cluding plethysmography and diffusion capacity, 
blood gases analysis independently of symptom per-
sistence. (moderate recommendation for, consensus 
reached when strong and weak recommendations are 
merged)
Remarks for Question 4: Should all patients with severe 
COVID-19 (WHO definition) have a pulmonary follow-
up including plethysmography and diffusion capacity, 
blood gases analysis independently of symptom persis-
tence? 49% (second survey: 64%) strong recommenda-
tion for, 44% (second survey: 36%) weak recommenda-
tion for, 2% (second survey: 0%) strong recommendation 
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against, 2% (second survey: 0%) weak recommendation 
against, 2% (second survey: 0%) no recommendation.
Question 5: Should Exercise Testing (e.g., 6MWD or 
Equivalent) Be Routinely Performed after COVID-19?
Literature Review
Increasing evidence suggests that a range of respira-
tory symptoms persists in a substantial number of CO-
VID-19 survivors. Several studies suggest that these occur 
independently of the initial degree of severity of the dis-
ease [23, 37, 38]. Respiratory symptoms such as dyspnea 
occurred in up to 40% of individuals 2–6 months follow-
ing COVID-19 [10, 25]. Exercise testing is commonly 
performed to investigate respiratory impairment, and the 
straightforward 6 min walking test (6MWT) is a useful 
tool to evaluate a range of chronic respiratory conditions 
[39]. Although the 6MWT has not been validated in CO-
VID-19-associated pulmonary impairment, it is being in-
creasingly employed to evaluate individuals after CO-
VID-19 to diagnose exercise-related hypoxia and evalu-
ate decreased exercise capacity [23, 25, 40]. In a Norwegian 
single-center study, half of the patients had hypoxia (SpO2 
<90%) during the 6MWT before hospital discharge [41]. 
Another study that evaluated patients with severe disease 
after 6 weeks found that walking distances in the 6MWT 
were under the predicted value for 79% of the partici-
pants, albeit without desaturation [42]. Data from a Swiss 
observational study acquired 4 months following severe/
critical COVID-19 also showed a decreased 6MWT dis-
tance, but with significant desaturation in such patients 
[20]. A Chinese study performed in 1,733 COVID-19 pa-
tients 6 months following COVID-19 observed that be-
tween 24–29% of patients had a 6MWT distance less than 
the lower normal range depending on depending on the 
severity of the SARS-CoV-2 infection [25]. In addition, 
the 6MWT has been employed as a useful investigation to 
monitor COVID-19 patients during rehabilitation [43, 
44]. To date no guideline exists that recommends the 
6MWT as a routine examination in patients following 
COVID-19.
Committee Discussion
The committee discussed that the form of exercise 
testing might depend on the local possibilities. A 6MWD 
should be performed as a minimum to detect exercise hy-
poxia in patients with otherwise normal lung functional 
testing. In case of suspected impaired oxygen uptake, 
CPET may be useful to determine the underlying pathol-
ogy.
SGP/SSP Recommendation
• Exercise testing (e.g., 6MWD or equivalent) is recom-
mended after COVID-19. (weak recommendation for, 
consensus reached)
Remarks for Question 5: Should exercise testing (e.g., 
6MWD or equivalent) be routinely performed after CO-
VID-19? 26% (second survey: 0%) strong recommenda-
tion for, 52% (second survey: 77%) weak recommenda-
tion for, 7% (second survey: 0%) strong recommendation 
against, 5% (second survey: 9%) weak recommendation 
against, 12% (second survey: 14%) no recommendation.
Question 6: Should Chest CT Scan Be Routinely 
Performed in Patients with Persisting Respiratory 
Symptoms after COVID-19?
Literature Review
A range of radiological abnormalities have been re-
ported following COVID-19 infection [45]. In addition to 
interstitial opacities, consolidations and pneumatoceles, 
air trapping suggestive of small airways disease and/or mi-
crovascular thrombosis has been described [45]. A 3 
months’ follow-up study from The Netherlands reported 
a reduction (but persistence) of ground-glass opacifica-
tion (GGO), bronchi(ol)ectasis, lines or bands, and fibrot-
ic changes in 86, 60, 64, and 26% of participants, respec-
tively [46]. The presence of an increased number of such 
abnormalities was associated with lower diffusion capac-
ity [46]. Specifically, radiological signs of fibrosis were as-
sociated with older age, decreased TLC, and oxygen de-
saturation in the 6MWT, but not dyspnea [46]. In a 4 
months’ follow-up, we found an association between mo-
saic hypo-attenuation and severe/critical COVID-19 that 
may indicate small airways involvement and/or microvas-
cular sequelae [20]. Although consolidations, interstitial 
involvement with sub-pleural lines, and ground-glass 
opacities had mostly resolved by 5 months, a Chinese 
Study on 1,733 participants observed that extensive radio-
logical abnormalities in CT scans were associated with 
more severe clinical courses of COVID-19 [25]. In addi-
tion, the authors reported an increased risk of diffusion 
impairment, depression, fatigue, and muscle weakness in 
the presence of more pronounced radiological abnormal-
ities [25]. A 6 months’ follow-up reported residual CT ab-
normalities in 62% of patients and fibrotic-like changes in 
one-third of patients with severe COVID-19 [47]. Such 
radiographic abnormalities were associated with older 
age, ARDS, extensive initial chest CT scan changes, and 
impaired diffusion capacity [47]. Importantly, 63% of pa-
tients with ARDS developed fibrotic-type changes after 6 
months, compared to 5% in non-ARDS patients [47].




While all the above follow-up studies provide valuable 
information on chest CT scan abnormalities, important 
questions on the long-term clinical and histologic conse-
quences remain unanswered to date: First, do fibrotic 
chest CT scan abnormalities reliably identify irreversible 
alterations after COVID-19-related ARDS? Second, what 
is the significance and outcome of other, nonfibrotic 
chest CT scan patterns such as GGOs that have been as-
sociated with irreversible ILD [48]. Finally, how do chest 
CT scan patterns in post-COVID-19 ARDS and ventila-
tor-induced lung damage differ from those abnormalities 
related to inflammatory pathways caused by COVID-19 
that may eventually progress to lung fibrosis in a small 
proportion of patients?
In summary, despite an increasing number of pub-
lished long-term follow-up studies, the evidence for ra-
diological patterns that enable prediction of a clinical 
course and/or prognosis after COVID-19 is still insuffi-
cient.
Committee Discussion
The committee agreed that, until further data is avail-
able, follow-up chest CT imaging should be performed in 
patients with unexplained respiratory symptoms and 
functional impairment after COVID-19. The protocol of 
the chest CT scan needs to be defined and is subject of 
current evaluations.
SGP/SSP Recommendation
• Chest CT scan is recommended to be routinely per-
formed in patients with persisting respiratory symp-
toms after COVID-19. (moderate recommendation 
for, consensus reached when strong and weak recom-
mendations are merged)
Remarks for Question 6: Should chest CT scan be rou-
tinely performed in patients with persisting respiratory 
symptoms after COVID-19? 40% (second survey: 68%) 
strong recommendation for, 42% (second survey: 32%) 
weak recommendation for, 2% (second survey: 0%) 
strong recommendation against, 7% (second survey: 0%) 
weak recommendation against, 9% (second survey: 0%) 
no recommendation.
Question 7: Should CPET Be Routinely Performed 
after COVID-19 with Persistent Symptoms?
Literature Review
To date few observational studies addressed this ques-
tion [11]. When addressing this question in July 2020, the 
ATS/ERS international task force provided no recom-
mendation for or against routine cardio-pulmonary exer-
cise testing, within 30–60 days post-COVID-19 pneumo-
nia [19]. Despite an agreement that CPET would be useful 
for the follow-up of the patients, concerns were raised 
regarding the potential risks of exposing health-care 
workers to aerosols in case of undiagnosed COVID-19 
infection. This concern does not apply to LC patients who 
are not carriers of an active infection. It has to be stressed 
that the task force was concerned exclusively about rou-
tine testing, and it recommended a case-by-case evalua-
tion for symptomatic patients (either new or persistent 
symptoms). Using a 1 min sit-to-stand test, the Short 
Physical Performance Battery (to assess lower extremities 
function) and the Barthel index (to assess performance 
for activities of daily life), Belli et al. [49] reported in a 
small retrospective study, abnormal physical and func-
tioning performances in 30–50% of 103 COVID-19 pa-
tients who survived hospitalization, at discharge, high-
lighting the need to establish an objective reference base-
line, e.g. by CPET, from which to monitor recovery over 
time. In a letter to the editor, Gao et al. [50] reported the 
CPET results performed in 10 rehabilitated patients with 
COVID-19, one month post-discharge, having observed 
reduced peak VO2 in all cases and decreased oxygen pulse 
in a vast majority. More recently, a small retrospective 
German study reported CPET results obtained by testing 
10 patients with persistent post-COVID-19 dyspnea. 
They found a reduced mean peak oxygen uptake at 73% 
of predicted value, a preserved mean peak work rate 
(92.4% of predicted value) and a high mean value of lac-
tate, supporting the hypothesis that post-COVID-19 dys-
pnea may be mostly related to muscular limitation [51]. 
In conclusion, there are currently no RCTs or prospective 
studies with sufficient numbers of patients to draw sound 
conclusions regarding the question of the indication to 
perform a routine CPET for patients with persistent 
symptoms after COVID-19.
Committee Discussion
The feasibility to perform routine CPET is limited in 
several centers. If available, the committee stresses the 
usefulness of CPET if unexplained gas exchange impair-
ment is present. CPET is also helpful to determine work 
inability in patients with reduced physical exercise capac-
ity. It has to be stated that the second survey was very close 
to reaching a consensus for a weak recommendation for 
performing routine CPET.
SGP/SSP Recommendation
• CPET is recommended to be routinely performed after 
COVID-19 with persistent symptoms. (moderate rec-
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ommendation for, consensus reached when strong 
and weak recommendations are merged)
Remarks for Question 7: Should CPET be routinely 
performed after COVID-19 with persistent symptoms? 
23% (second survey: 14%) strong recommendation for, 
42% (second survey: 68%) weak recommendation for, 5% 
(second survey: 9%) strong recommendation against, 
16% (second survey: 9%) weak recommendation against, 
14% (second survey: 0%) no recommendation.
Question 8: Should Patients with Persistent Symptoms 
after COVID-19 Have Access to Specialized 
Multidisciplinary Post-COVID-19 Clinics or 
Networks?
Literature Review
Following the acute phase of COVID-19, approxi-
mately 1 out of 10 persons do not recover and may seek 
healthcare advice with a variety of symptoms such as a 
reduced exercise capacity, cough, thoracic pain, fatigue, 
and neuropsychological problems. Symptoms may over-
lap, affect any organ system and impact on quality of life. 
In the majority of patients, these symptoms resolve and 
rarely persist beyond 12 weeks after the acute phase. A 
recent US study found that only 65% of people had re-
turned to their previous level of health 14–21 days after a 
positive test [52]. However, symptoms may persist for 
significantly longer, with fever, fatigue and breathlessness 
that may even recur in some individuals [11, 25, 53]. The 
LC syndrome refers to individuals with persistent symp-
toms extending beyond 4–12 weeks after the acute phase 
that are not explained by an alternative diagnosis [11, 15]. 
These patients may need therapeutic advice with special-
ist investigation, rehabilitation, psychological support 
and further follow-up. To address these issues, post-CO-
VID/LC assessment clinics have been established to sup-
port GPs after initial evaluation. An increasing number 
of LC clinics are being installed and specific guidelines 
have been formulated [15].
These clinics should ideally provide a multidisci-
plinary assessment by providing necessary resources for 
the care of patients recovering from COVID-19 [54]. 
Since the exact nature of the multiple deficits is unclear, 
one objective of such clinics is to ensure continuity of care 
and accurately track important health related outcomes. 
The multi-professional team comprises pulmonologists, 
rheumatologists, neurologists, psychiatrists, cardiolo-
gists, otolaryngologists, dermatologists, internal medi-
cine physicians, nutritionists, physiotherapists, nephrol-
ogists, and others.
Committee Discussion
In general, the majority of the panel recognizes the 
importance of such clinics and several comments to the 
question highlight the importance of a multi-/interdis-
ciplinary and multi-professional approach due to the 
wide range of symptoms. However, access may be lim-
ited for some patients where no such clinics exist in the 
vicinity. Since the benefit of such centers is not based 
on a body of evidence, tertiary centers should provide 
reasonable efforts to include patients in registries and 
clinical trials.
SGP/SSP Recommendation
• Patients with persistent symptoms after COVID-19 
are recommended to have access to specialized multi-
disciplinary post-COVID-19 clinics or networks. 
(moderate recommendation for, consensus reached 
when strong and weak recommendations are merged)
Remarks for Question 8: Should patients with persis-
tent symptoms after COVID-19 have access to specialized 
multidisciplinary post-COVID-19 clinics or networks? 
65% (second survey: 55%) strong recommendation for, 
28% (second survey: 41%) weak recommendation for, 0% 
(second survey: 0%) strong recommendation against, 2% 
(second survey: 0%) weak recommendation against, 5% 
(second survey: 5%) no recommendation.
Question 9: Should Patients after COVID-19 Who 
Present with New Onset Obstructive Lung Disease 
Have Empiric Topic Inhaled or Systemic Steroid 
Treatment?
Literature Review
Bronchiolitis and bronchial inflammation are com-
mon findings with many viral diseases, specifically in 
children [55]. Bronchiolitis leads to discrepancies be-
tween lung opacities and poor oxygenation while compli-
ance is preserved [56]. On chest CT, small airways disease 
manifests by opacities with mosaic patterns [20, 45]. The 
long-term outcome of these changes and the usefulness 
of corticosteroids remain unclear. Prior inhaled cortico-
steroid (ICS) use is not significantly associated with CO-
VID-19 incidence in patients with either COPD or asth-
ma or early clinical outcomes among patients with CO-
VID-19 [57–59]. However, ICS may improve 
COVID-19-related bronchial syndromes, like for most 
other viral exacerbations in asthma or COPD [60].
Committee Discussion
The frequency of patients presenting with new-onset 
pulmonary obstructive disease after COVID-19 is un-




clear and not consistently addressed in the literature. 
Some patients might have undiagnosed underlying asth-
ma or COPD. Nevertheless, some radiological findings 
suggest the presence of small airway disease. An empiri-
cal treatment trial may be performed on a case-by-case 
basis.
SGP/SSP Recommendation
• Patients after COVID-19 who present with new ob-
structive lung disease are recommended to be offered 
empiric topic inhaled or systemic steroid treatment. 
(moderate recommendation for, consensus reached 
when strong and weak recommendations are merged)
Remarks for Question 9: Should patients after CO-
VID-19 who present with new onset obstructive lung 
disease have empiric topic inhaled or systemic steroid 
treatment? 33% (second survey: 36%) strong recom-
mendation for, 37% (second survey: 36%) weak recom-
mendation for, 5% (second survey: 5%) strong recom-
mendation against, 5% (second survey: 9%) weak rec-
ommendation against, 21% (second survey: 14%) no 
recommendation.
Question 10: Should Patients after COVID-19 Who 
Present with Persistent Cough Have Empiric Inhaled 
Topic Steroids?
Literature Review
Cough is among the most common symptoms associ-
ated with viral respiratory infections. 36–43% of people 
with a viral upper respiratory tract infection still have 
cough 3 months after the infection [61]. Cough is not the 
primary complaint occurring after COVID-19 but has 
been reported. In an Italian study, 60 days after initial 
symptom onset, only 16% of patients complained about 
persistent cough [10]. Similarly, in a study of formerly 
hospitalized UK patients, 12% of patients reported cough 
90 days after onset of initial symptoms [62]. However, in 
such individuals, cough is a common complaint leading 
to GP consultations, increased health costs, and an im-
paired quality of life. ICS reduce the numbers of inflam-
matory cells in the airways and downregulate multiple 
inflammatory genes encoding for cytokines, chemokines, 
inflammatory enzymes, and receptors [63]. Although the 
suppression of mucosal inflammation is associated with 
a clinically relevant reduction of bronchial hyperreactiv-
ity, the effect of inhaled steroids for other causes of cough 
remains controversial [64]. Moreover, recent guidelines 
differ in their recommendations of ICS for chronic cough 
management [65, 66].
The role of ICS during the acute phase of COVID-19 
is different. While preparing the current guidelines (be-
tween survey 1 and survey 2), an open-label RCT investi-
gating inhaled budesonide given within 7 days of symp-
tom onset was pre-published [67]. The likelihood of re-
quiring urgent care, emergency department consultation 
and hospitalization was significantly reduced in adults 
inhaling budesonide, providing first evidence for an af-
fordable and effective intervention. Additional studies 
are required to confirm these findings.
Committee Discussion
Methacholine testing to investigate chronic cough in 
patients after COVID-19 infection is rarely performed 
due to increased infectious risks in case of persistent viral 
replication. Other causes of chronic cough should be 
evaluated and treated if identified. The committee dis-
cussed an empiric therapy of ICS in cough following CO-
VID-19 and recognizes that the evidence for inhaled ste-
roids in non-COVID-19 post-viral cough is still low, with 
inconsistent recommendations formulated by the pul-
monary societies. No clinical trials exist in persistent 
cough related to COVID-19. Since ICS are easy to apply 
with an acceptable safety profile, a limited trial of 4–6 
weeks may be an option to treat cough after COVID-19. 
The change between survey 1 (strong recommendation 
for: 12%) and 2 (strong recommendation for: 32%) may 
have been caused by the recent pre-publication about ICS 
in acute COVID-19 infection [67] or personal experience. 
In patients with preexistent asthma or eosinophilic air-
way disease, ICS should be continued as the mainstay of 
therapy.
SGP/SSP Recommendation
• Patients after COVID-19 who present with persistent 
cough are recommended to have empiric inhaled top-
ic steroids. (moderate recommendation for, consensus 
reached when strong and weak recommendations are 
merged)
Remarks for Question 10: Should patients after CO-
VID-19 who present with persistent cough have empiric 
inhaled topic steroids? 12% (second survey: 32%) strong 
recommendation for, 49% (second survey: 45%) weak 
recommendation for, 5% (second survey: 5%) strong rec-
ommendation against, 12% (second survey: 9%) weak 




Question 11: Should Patients after COVID-19 Who 
Present with Interstitial Abnormalities after Exclusion 
of an Active Infection Receive an Empiric Systemic 
Steroid Trial?
Literature Review
Post-infectious inflammatory processes often include 
organizing pneumonia (OP) that may occur after CO-
VID-19 infection [68–71]. OP generally improves with 
oral corticosteroids and recent observations suggest that 
patients with interstitial abnormalities after COVID-19 
may benefit from systemic steroid trials [72]. This study 
showed that patients with symptomatic infiltrates at 6 
weeks and significant persistent functional deficits im-
proved with an average of 26 mg/day of prednisone with 
a dose-reduction scheme over 6 weeks. Such treatment 
was associated with a mean relative increase in transfer 
factor by 31.6% and FVC by 9.6%, as well as significant 
symptomatic and radiological improvement. This obser-
vational study was not randomized but showed a marked 
clinical improvement of these patients in less than 12 
weeks overall, after a careful initial evaluation. Further-
more, this study raises the opportunity to treat OP related 
lesions after COVID-19 infections with low doses sys-
temic steroids, potentially preventing persistent symp-
tomatic interstitial lung disease [72].
Committee Discussion
The committee recognizes a steroid trial as a possible 
treatment approach if, e.g., OP or bronchiolitis can be diag-
nosed and acute infection has been ruled out. As no RCT is 
currently published, this remains a case-by-case decision, 
which should be considered especially if lung function is 
impaired and the patient remains symptomatic.
SGP/SSP Recommendation
• Patients after COVID-19 who present with interstitial 
abnormalities after exclusion of an active infection are 
recommended to be evaluated to receive an empiric 
systemic steroid trial. (moderate recommendation for, 
consensus reached when strong and weak recommen-
dations are merged)
Remarks for Question 11: Should patients after CO-
VID-19 who present with interstitial abnormalities after 
exclusion of an active infection receive an empiric sys-
temic steroid trial? 16% (second survey: 14%) strong rec-
ommendation for, 40% (second survey: 59%) weak rec-
ommendation for, 5% (second survey: 9%) strong recom-
mendation against, 26% (second survey: 5%) weak 
recommendation against, 14% (second survey: 14%) no 
recommendation.
Question 12: Should Patients after COVID-19 Who 
Present with Signs of Pulmonary Fibrosis Receive 
Specific Antifibrotic Drugs?
Literature Review
Recent evidence showed that antifibrotic drugs are 
well tolerated and provide a benefit in in progressive fi-
brosing lung disease independently of the underlying pa-
thology [73, 74]. Pulmonary fibrosis is a complication 
that occurs after COVID-19 [75]. Mechanisms of disease 
may overlap between both type of disorders, including 
susceptibility in men and increased age, as well as cellular 
mechanisms (e.g., ACE2 involvement) [76]. This compli-
cation of COVID-19 has raised concern within the pul-
monary community, although the precise frequency of 
complicating fibrotic lung disease is unknown with cur-
rently only case series that exist. Recent publications sug-
gest that antifibrotic drugs may be beneficial in patients 
with fibrosis after COVID-19 [37, 76, 77]. Although RCTs 
are still lacking, several studies with nintedanib 
(NCT04619680, NCT04541680, NCT04338802) and pir-
fenidone (NCT04607928, NCT04653831) are currently 
ongoing.
Committee Discussion
The committee agreed that evidence from ongoing 
RCT should be awaited to evaluate effects of antifibrotic 
drugs in COVID-19-induced fibrosis. According to the 
committees’ personal experience, fibrosis after CO-
VID-19 is usually nonprogressive. Antifibrotic treatment 
may be indicated if underlying progressive ILD (i.e., IPF) 
has been fortuitously discovered. Otherwise, patients 
should be evaluated on a case-by-case basis for compas-
sionate use.
SGP/SSP Recommendation
• It is unclear whether patients after COVID-19 who 
present with signs of pulmonary fibrosis should re-
ceive specific antifibrotic drugs. (suggestion for no 
recommendation, no consensus)
Remarks for Question 12: Should patients after CO-
VID-19 who present with signs of pulmonary fibrosis re-
ceive specific antifibrotic drugs? 9% (second survey: 5%) 
strong recommendation for, 28% (second survey: 32%) 
weak recommendation for, 7% (second survey: 0%) 
strong recommendation against, 16% (second survey: 
9%) weak recommendation against, 40% (second survey: 
55%) no recommendation.




Question 13: Should Patients after COVID-19 
Who Present with Persistent Respiratory Symptoms 
Undergo a Rehabilitation Program?
Literature Review
Current evidence for rehabilitation after COVID-19 is 
weak but steadily increasing [78]. Clinical trials are ongo-
ing to evaluate the effects of pulmonary rehabilitation af-
ter COVID-19 [11]. Interim guidance from the European 
Respiratory Society has already recommended post-CO-
VID-19 rehabilitation [19]. Similarly, the German S3 
Recommendations propose post-COVID-19 rehabilita-
tion [27].
Committee Discussion
The committee strongly supports the panel decision to 
recommend pulmonary rehabilitation in patients with 
ongoing respiratory symptoms.
SSP Recommendation
• Patients after COVID-19 who present with persistent 
respiratory symptoms are recommended to undergo a 
rehabilitation program. (strong recommendation for, 
consensus reached)
Remarks for Question 13: Should patients after CO-
VID-19 who present with persistent respiratory symp-
toms undergo a rehabilitation program? 86% (second 
survey: 91%) strong recommendation for, 7% (second 
survey: 5%) weak recommendation for, 0% (second sur-
vey: 0%) strong recommendation against, 0% (second 
survey: 5%) weak recommendation against, 7% (second 
survey: 0%) no recommendation.
Future Directions and Research Questions
Despite the lack of a clear definition of LC, persist-
ing respiratory symptoms and pulmonary function im-
pairment more than 1 month after COVID-19 may in-
dicate LC syndrome. A broadly supported, pragmatic, 
and clear definition is required to standardize research 
and support future therapeutic strategies. Moreover, 
evidence for the management and treatment of pulmo-
nary manifestations of LC is still lacking. The European 
Respiratory Society provided initial interim guidance 
on rehabilitation [19], but many aspects of disease 
management and specific treatment approaches re-
main unclear to date for practitioners. Clinical trials to 
address several of the questions raised by the commit-
tee are currently ongoing [11]. While awaiting addi-
tional evidence, we herein provide interim guidance 
for patient care based on the experience of pulmonolo-
gists from Switzerland and the results of our survey-
based consensus.
Conclusions
Physicians are facing patients with symptoms and 
functional impairment that need to be addressed. These 
consensus-based recommendations provide an interim 
support for practitioners awaiting results from ongoing 
and future trials. The recommendations need to be care-
fully reconsidered and revised as new knowledge emerges 
about pulmonary LC.
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